The soluble urokinase-type plasminogen activator receptor as a biomarker for survival and early treatment effect in metastatic colorectal cancer

Kristian Blomberg, Torben F. Hansen, Claus L. Brasen, Jeppe B. Madsen, Lars H. Jensen, Caroline B. Thomsen*

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

The soluble urokinase-type plasminogen activator receptor (suPAR) is prognostic for overall survival (OS) in colorectal cancer (CRC). Our study explored the association between baseline suPAR and OS and progression-free survival (PFS) in metastatic CRC (mCRC). It is also the first study to explore the association between the initial change in suPAR level and OS, PFS and the first CT response evaluation. The study included 132 patients with mCRC treated with chemotherapy (FOLFIRI) with or without an EGFR-inhibitor. Blood samples were drawn before the first treatment cycle and in between the first and second treatment cycle. suPAR levels were determined using an ELISA assay. Using the Kaplan-Meyer method, we demonstrated a significantly shorter OS for patients with suPAR levels above the median (HR = 1.79, 95%CI = 1.10–2.92, p = 0.01). We also showed association between plasma suPAR level, gender and performance status (PS). However, we could not show any association with PFS, and analysis on the change in suPAR level provided no significant results. The results showing association between baseline suPAR and OS are in line with previous findings.

Original languageEnglish
Article number5100
JournalCancers
Volume13
Issue number20
Number of pages11
ISSN2072-6694
DOIs
Publication statusPublished - 12. Oct 2021

Bibliographical note

Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.

Keywords

  • Metastatic colorectal cancer
  • Monitoring
  • SuPAR

Fingerprint

Dive into the research topics of 'The soluble urokinase-type plasminogen activator receptor as a biomarker for survival and early treatment effect in metastatic colorectal cancer'. Together they form a unique fingerprint.

Cite this